News | July 03, 2025
WuXi XDC announces mechanical completion of Singapore site
The site, spanning approximately 25,000 square meters, is expected to commence operations by the end of 2025
The site, spanning approximately 25,000 square meters, is expected to commence operations by the end of 2025
WuXi XDC's fully integrated ADC discovery service platform will significantly boost the speed and efficiency of LigaChem's ADC development programs
The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network
IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate
Boostimmune will have access to WuXi XDC's fully integrated one-stop bioconjugate platform
This is the second line opened this year for parenteral drug product clinical and commercial manufacturing, with an annual capacity of 10 million units
This new facility integrates multi-channel chip, micro-mixer system, and complex preparation system into a multi-channel micro-mixer core LNP manufacturing platform
This biopharmaceutical facility is one most significant private sector investment ever in the Middletown region
WuXi STA opens a new large scale continuous manufacturing plant
Subscribe To Our Newsletter & Stay Updated
